Management
Arthur Kuan
Chief Executive Officer
James Burke, MD
Chief Medical Officer
Georg Roth, PhD
Chief Technical Officer
Bing Kung
VP, Business Development
Amy Steele
VP, Finance, Accounting & Administration

Board of Directors
Arthur Kuan
Chief Executive Officer
Ronald Cheng
Managing Director, Wellchamp Capital
Brian Liu
Principal, Longitude Capital
Jim Mulé, PhD
Director of Cell-based Therapies, Moffitt Cancer Center
Osamu Nakanishi, PhD
Kissei Pharmaceutical
Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics
Jue Pu
Lepu Medical
Simone Song
Senior Partner, ORI Capital
Arthur Kuan
Chief Executive Officer
James Burke, MD
Chief Medical Officer
James is the Chief Medical Officer at CG Oncology and is responsible for clinical and translational development. Inspired by early gene therapy studies and the diagnosis of his father with cancer, James decided that gene and immunotherapy represented a potentially powerful tool to fight cancer and other incurable disease. James has over 20 years of preclinical and clinical experience in the field of gene and immunotherapy. James was previously CMO at Turnstone Biologics and Jennerex Biotherapeutics / SillaJen where he oversaw global clinical development for oncolytic virus therapies. Prior to Jennerex, he was Associate Director of Clinical Research at Cell Genesys. As a hematologist and oncologist, James remains committed to delivering excellent clinical care to his patients, while pushing for even better outcomes for patients at CG Oncology. James is active in the clinic. In Montana he brought the first gene and immunotherapy clinical studies to the state while establishing a clinical trials center for patients. James earned a BS in Biochemistry from University of California, San Diego and an MD from Georgetown University. He completed a general internal medicine residency at University of California, San Diego followed by a Hematology-Oncology Fellowship at University of California, San Francisco.
Georg Roth, PhD
Chief Technical Officer
Bing Kung
VP, Business Development
Amy Steele
VP, Finance, Accounting & Administration
Arthur Kuan
Chief Executive Officer
Ronald Cheng
Managing Director, Wellchamp Capital
Brian Liu
Principal, Longitude Capital
Jim Mulé, PhD
Director of Cell-based Therapies, Moffitt Cancer Center
Osamu Nakanishi, PhD
Kissei Pharmaceutical
Leonard Post, PhD
Chief Scientific Officer, Vivace Therapeutics
Jue Pu
Lepu Medical
Simone Song
Senior Partner, ORI Capital